Effectiveness of the adapted Unified Protocol (UP-MSo) in relapsing-remitting multiple sclerosis with overweight/obesity: A pre-registered randomized controlled trial on emotion regulation, eating behavior, and neurological outcomes.

Mult Scler Relat DisordJul 4, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

Maria Consuelo San Martín, Marcos Domic-Siede, Marcela Soto et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the adapted Unified Protocol (UP-MSo) for emotion regulation and eating behaviors in adults with relapsing-remitting multiple sclerosis (RRMS) and overweight/obesity. The study found significant improvements in body mass index (BMI) and Expanded Disability Status Scale (EDSS) scores in the intervention group compared to standard care, with p-values of .030 and <.001, respectively.

Key findings

  • Significant reductions in BMI were observed in the intervention group (p=.030, ηp²=.07).
  • Weight decreased significantly in the intervention group compared to standard care (p=.024, ηp²=.07).
  • EDSS scores improved significantly in the intervention group (p<.001, ηp²=.31).
  • Within the intervention arm, there were improvements in emotion regulation and emotional eating.

Why it matters

The findings suggest that emotion-focused interventions may effectively address both psychological and physical health outcomes in patients with RRMS and obesity, potentially improving overall management of the condition.

Source

PubMed · PMID 42431140

Published in Mult Scler Relat Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.